Free Trial

Heron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Heron Therapeutics logo with Medical background

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.91 and traded as high as $2.07. Heron Therapeutics shares last traded at $2.00, with a volume of 1,096,766 shares traded.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright assumed coverage on Heron Therapeutics in a research report on Monday, June 9th. They set a "buy" rating and a $6.00 price target for the company. Needham & Company LLC restated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th. Finally, Wall Street Zen upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th.

Get Our Latest Research Report on Heron Therapeutics

Heron Therapeutics Price Performance

The stock has a market capitalization of $305.12 million, a PE ratio of -33.33 and a beta of 1.16. The stock has a fifty day moving average of $2.03 and a 200-day moving average of $1.92.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analysts' expectations of $37.08 million. Equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in Heron Therapeutics in the fourth quarter valued at $208,000. Point72 Asset Management L.P. acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth about $4,706,000. Principal Financial Group Inc. raised its position in shares of Heron Therapeutics by 10.6% during the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 10,909 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth about $459,000. Finally, JPMorgan Chase & Co. raised its position in shares of Heron Therapeutics by 172.2% during the 4th quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock worth $861,000 after acquiring an additional 356,053 shares in the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

About Heron Therapeutics

(Get Free Report)

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading

Should You Invest $1,000 in Heron Therapeutics Right Now?

Before you consider Heron Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.

While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential
Time to Cash Out? 5 Stocks to Drop Before Earnings

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines